论文部分内容阅读
今年5月,国家卫生计生委、国家发改委等7部门联合发布首批国家药品价格谈判结果,引起巨大的社会反响。与之前公立医院的采购价格比较,3种谈判药品降价幅度在50%以上,这不仅对患者是一个利好,也使药品价格国家谈判首次进入公众的视线。但随之而来的问题是,谈判好的药价在各地遇到落地难的问题,国家药品价格谈判对制药企业最大的吸引力来自以价博量后的医保报销,而目前中国3种覆盖不同层面的医保,分属两个部门管理,这成为国家药品价格
In May this year, the National Health and Family Planning Commission, the National Development and Reform Commission and other seven departments jointly released the first national drug price negotiations, causing great social repercussions. Compared with the purchase price of public hospitals in the past, the price of the three negotiated drugs was reduced by more than 50%, which is not only good for the patients but also makes the negotiation of the drug prices into the public’s eyes for the first time. But the ensuing problem is that negotiating a good drug prices across the country encountered the difficult landing problems, the national drug price negotiations on the pharmaceutical industry’s biggest attraction from the medical insurance after the amount of Medicare reimbursement, and now China’s three kinds of coverage Different levels of health insurance, belong to the management of two departments, which became the national drug prices